What?

IntroDia is the largest global type 2 diabetes survey ever conducted to mainly focus on the early physician–patient conversations.

Read more

Why?

IntroDia will explore how physicians and patients perceive early type 2 diabetes conversations and how this influences patient wellbeing and other self-reported outcomes. It will ultimately help to create effective solutions for the long-term type 2 diabetes management.

Read more

How?

Mainly via online questionnaires gathering data from approximately 17,000 respondents in 26 countries.

Read more

Insights

Physician and patient insights from the IntroDia Survey.

Read more

What is IntroDia?

Being diagnosed with type 2 diabetes is an important life event. And the moment when another oral medication may be required to maintain blood glucose levels can also be highly significant.

IntroDia is the largest global type 2 diabetes survey ever conducted that focuses on early conversations – providing key insights into how physicians and patients interact at these two important moments of the treatment journey.

IntroDia is sponsored by the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance and developed in partnership with the International Diabetes Federation (IDF).

The aim of IntroDia is to identify important insights into the early physician-patient conversations, which will help to develop tools and resources to support physicians and people with type 2 diabetes to improve long-term diabetes care.

Why?

The early physician–patient conversations are important to ensure patients get started on the right foot. IntroDia will explore how patients and physicians perceive early type 2 diabetes conversations and how this could be related to patient wellbeing and other self-reported outcomes.

Some of the issues the IntroDia survey will explore include:

  • How to support the early type 2 diabetes conversations between patients and physicians
  • What do patients recall being told during the conversations in which they were diagnosed with type 2 diabetes or when additional medication is required?
  • What is the experience for physicians in these early conversations? What challenges do they face?
  • What solutions will support even better conversations?

How?

IntroDia involves approximately 17,000 respondents (more than 6,500 physicians and 10,000 patients) in 26 countries.

IntroDia is mainly being conducted via online questionnaires, and face-to-face interviews in some countries.

IntroDia – developed with experts and healthcare professionals

The survey was created in collaboration with a multidisciplinary advisory board. The members include healthcare professionals and experts from the fields of behavioural psychology, primary care, endocrinology and nursing.

The IntroDia Advisory Board

Dr Steven Edelman

Dr Steven Edelman

USA

Endocrinologist

Dr William Polonsky

Dr William Polonsky

USA

Behavioural Psychologist

Dr Matthew S Capehorn

Dr Matthew S Capehorn

UK

Primary Care Physician

Dr Ms Su Down

Ms Su Down

UK

Nurse Consultant in Diabetes

Ms Anne Belton

Ms Anne Belton

Canada

Diabetes Nurse Educator, Vice President of the International Diabetes Federation

Dr Aus Alzaid

Dr Aus Alzaid

Saudi Arabia

Diabetologist

Insights

First physician insights from IntroDia

The first data from patient respondents from the IntroDia Survey were presented at the ADA 75th Scientific Sessions in June 2015 and the 51st Annual EASD Scientific Meeting in September 2015.

The results showed that the quality of patient-physician communication at both the ‘diagnosis’ and at a later moment, when additional medication was prescribed (‘add-on’), was linked to future patient self-care and well-being.

Key insights included:

  • Patients distinguish three types of physician statements that contribute to communication quality: ‘encouraging’, ‘collaborative’ and ‘discouraging’
  • When physicians used ‘encouraging’ and ‘collaborative’ statements, patients’ perception of the communication quality significantly improved. Using ‘discouraging’ statements had the opposite effect
  • Those who recalled better quality of communication when interacting with their physicians reported reduced diabetes-related emotional distress, improved diet and exercise, as well as better medication adherence

”According to Dr William Polonsky, USA, Behavioural Psychologist and member of the IntroDia Advisory Panel: “IntroDia is the largest study of its kind to highlight how effective communication between physicians and people with type 2 diabetes around the world can have a powerful influence on how an individual thinks about and manages their condition. These latest patient data reinforce how important it is for us to get early management right, for the successful long-term management of the disease."

Click here to read the full press release

First physician insights from IntroDia

The first insights from more than 6,700 surveyed physicians were presented at the American Diabetes Association’s (ADA) 74th Scientific Sessions® in June 2014 and at the 50th Annual European Association for the Study of Diabetes (EASD) Scientific Meeting in September 2014.
The results showed:

  • Over three quarters of the surveyed physicians (76-100 percent across 26 countries) agreed that conversations at diagnosis impact the way people with Type 2 Diabetes (T2D) accept their condition, as well as their treatment adherence
  • The challenges most commonly reported by physicians during diagnosis conversations were that patients do not always keep up with the required changes, returning to old habits. Physicians also reported not having enough time to carry out important conversations with patients
  • Physicians reported that treatment success is dependent on both behavioural change and the efficacy of medication in approximately equal measures
  • Most physicians surveyed (92 percent) also indicated they would like tools to help people with T2D sustain behavioural change.

Click here to read the full press release

Click here to hear more from members of the IntroDia Advisory Board on the results

Watch this space for the first patient insights - coming soon!

Contact Us

To contact us, please email: info@introdia.com